{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:16:39Z","timestamp":1775697399294,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.blre.2012.06.002","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T20:02:46Z","timestamp":1341950566000},"page":"205-211","source":"Crossref","is-referenced-by-count":51,"title":["Front-line therapy in polycythemia vera and essential thrombocythemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2012.06.002_bb0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2012.06.002_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2012.06.002_bb0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.blre.2012.06.002_bb0020","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0030","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2 V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0035","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0040","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2001","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2012.06.002_bb0055","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0065","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0070","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0090","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0095","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat patients with polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0100","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2012.06.002_bb0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2012.06.002_bb0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The hematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0115","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0120","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2012.06.002_bb0125","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0135","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk thrombocythaemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0140","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed accordin to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0150","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0160","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0165","first-page":"17","article-title":"From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0170","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0175","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0180","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0190","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0200","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0205","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0210","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0215","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an International Working Group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200666010-00006","article-title":"Anagrelide: a review of its use in the management of essential thrombocythemia","volume":"66","author":"Wagstaff","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2012.06.002_bb0230","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2012.06.002_bb0235","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relation to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0240","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0245","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V110.11.3547.3547","article-title":"Non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed patients with essential thrombocythemia. The ANAHYDRET-Study","volume":"110","author":"Gisslinger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0255","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon-alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0265","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2012.06.002_bb0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2012.06.002_bb0275","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0280","first-page":"1281","article-title":"Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia","volume":"91","author":"Samuelsson","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2012.06.002_bb0285","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2012.06.002_bb0290","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2012.06.002_bb0295","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2012.06.002_bb0300","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM199905063401801","article-title":"Reye's syndrome in the United States from 1981 through 1997","volume":"340","author":"Belay","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2012.06.002_bb0305","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2012.12","article-title":"How to manage children and young adults with myeloproliferative neoplasms","volume":"26","author":"Barbui","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0310","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/leu.2011.306","article-title":"How to manage essential thrombocythemia","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2012.06.002_bb0315","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2012.06.002_bb0320","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1200046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1200046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:48:57Z","timestamp":1594392537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1200046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0268960X1200046X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2012.06.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}